Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen to fuel tumors and maximize the therapeutic effects of radiotherapy.

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Circadacare is a health technology company focused on enhancing the quality of life for older adults through innovative solutions in care environments. The company specializes in developing integrated systems that combine lighting, sensors, and software technology to synchronize the day-night cycle for residents, thereby improving their overall well-being. By translating scientific principles into practical applications, Circadacare aims to create care home lighting services that not only benefit the residents but also support staff efficiency. The solutions provided by Circadacare are designed to operate seamlessly, requiring minimal training for staff, while delivering both care outcome improvements for older adults and cost benefits for operators of nursing homes, care villages, and dementia care centers.

Axial3D specializes in 3D printing technology for healthcare, focusing on creating precise, patient-specific anatomical models derived from CT and MRI scan data. By providing a unique Online Ordering Portal, they enable clinicians to securely upload scans, allowing Axial3D's expert team to generate accurate physical models of patients' anatomy. These 3D printed models enhance the understanding of medical abnormalities, promote innovative surgical techniques, and ultimately improve surgical outcomes. The company's approach bridges the gap between technology and medicine, empowering surgeons and medical practitioners to effectively plan and rehearse complex procedures, thereby advancing the standards and efficiency of surgical interventions.

MediMusic is a health technology company that focuses on developing a medical technology platform aimed at alleviating pain, anxiety, and stress through the power of music. The platform leverages artificial intelligence to generate personalized playlists tailored to individual patient needs. By using soothing music, MediMusic's solution aims to lower heart rates and stimulate the vagus nerve, promoting a positive physiological response. This innovative approach not only helps in managing stress and anxiety but also enhances the effectiveness of pain medication, offering a holistic treatment option for patients dealing with various health challenges, including dementia and anxiety-related disorders.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Kaydiar is a medical device company focused on developing innovative, cost-effective solutions for wound care, particularly for pressure injuries. They specialize in offloading technology, creating products such as orthotic devices, bed mattresses, wheelchair cushions, and prosthetic sleeves to relieve pressure and promote healing.

Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.

ScubaTx focuses on developing an organ preservation system that utilizes the Persufflation method, which is known for its effectiveness in preserving organs during transportation. By enhancing the condition of grafts during preservation, ScubaTx enables healthcare providers to expand the availability of viable organs for transplantation. The company aims to improve organ preservation practices through innovative software design, ultimately delivering significant cost savings to healthcare providers. This advancement not only enhances the quality of organ transplants but also contributes to increasing the overall supply of life-saving organs available to patients in need.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases. Utilizing a research and development platform that leverages insights into the role of activated fibroblast populations in disease, the company aims to create therapeutics that target fibroblast-mediated effects on immune cells. This approach is designed to enhance the medical industry's ability to combat and potentially cure rare and life-threatening conditions. Through its work, Mestag Therapeutics seeks to contribute meaningful advancements in the treatment landscape for these challenging diseases.

Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Lentitek is a biotechnology company focused on developing gene and gene-modified cell therapies, particularly aimed at treating cancer. The company is dedicated to enhancing the accessibility of innovative cures by increasing the yield of lentiviral vectors, which are critical for gene therapy applications. Lentitek employs a proprietary method that utilizes a novel promoter to significantly boost lentiviral production, potentially increasing yields by tenfold or more. This innovative approach not only improves the efficiency of lentivirus production but also aims to reduce overall production costs for healthcare providers, thereby facilitating broader availability of advanced therapeutic options for patients.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, a group of rare genetic disorders affecting the brain's white matter. The company aims to disrupt existing treatment practices by creating a therapy that addresses the root cause of these diseases, specifically targeting the mutated TUBB4a gene implicated in TUBB4a Leukodystrophy. By leveraging groundbreaking research, SynaptixBio is dedicated to providing potentially curative options for patients suffering from this acute subset of leukodystrophies. The company also maintains an online platform to engage with customers and address inquiries, ensuring transparency and accessibility of information about their advancements.

Siloton is a medical device manufacturer focused on creating diagnostic imaging devices for ophthalmology. The company specializes in developing advanced portable optical coherence tomography devices designed to address challenges in eye care. Their hand-held sub-surface imaging technology allows for home-based scanning, providing users with the ability to monitor their eye health and contribute to the prevention of avoidable blindness.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.

Nuclera is a biotechnology company specializing in an automated protein prototyping system aimed at enhancing drug discovery processes. Its eProtein Discovery system enables researchers to rapidly produce and test high-quality, soluble, and active proteins, significantly accelerating protein projects. By integrating technology such as cell-free protein synthesis and digital microfluidics, Nuclera provides a high-throughput platform for automated protein access. This innovative approach allows scientists to obtain reliable proteins within a short timeframe, facilitating faster progress in their research and contributing to more efficient drug development efforts.

BiVictriX Therapeutics Ltd. is a UK-based company focused on drug discovery and development, specializing in bispecific antibody drug conjugates aimed at addressing unmet needs in blood cancer treatment. Established in 2016 and located in Alderley Edge, the company employs its proprietary Bi-Cygni technology to create innovative therapeutics, particularly for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX's expertise encompasses oncology, hematological malignancies, immunotherapy, and antibody research, positioning it as a key player in the development of advanced biotherapeutics and drug development initiatives.

Fuse Diagnostics focuses on manufacturing diagnostic products that deliver lab-quality information across various sectors. The company aims to provide innovative and cost-effective testing solutions that ensure laboratory accuracy for applications in food and water testing, bioprocessing, and cell biology research. By offering low-cost test kits equipped with integrated readout technology, Fuse Diagnostics enables businesses to obtain rapid and reliable results, thereby enhancing the accessibility and efficiency of diagnostic testing.

LIfT BioSciences is a biotechnology company based in London, England, founded in 2016. The company specializes in a novel allogeneic innate immuno-cell therapy platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). This platform enables the large-scale production of Immunomodulatory Alpha Neutrophils (IMANs) derived from induced pluripotent stem cells (iPSCs) for various therapeutic applications. LIfT BioSciences focuses on developing CAR neutrophil cell therapies that address the limitations of existing treatments for solid tumors. These therapies work by directly attacking tumors and indirectly enhancing the immune response, effectively transforming the tumor microenvironment to recruit additional immune cells for a more robust and lasting attack on the cancer. By employing proprietary enhancement media and genetic engineering, LIfT BioSciences aims to significantly increase the cancer-fighting capabilities of these engineered cells, potentially providing patients with greatly improved therapeutic outcomes.

The University of Bristol is a red brick research university that offers a range of educational courses and services. The university is organized into six academic facilities: Faculty of Arts, Faculty of Engineering, Faculty of Medical and Veterinary Sciences, Faculty of Science, Faculty of Medicine and Dentistry, and Faculty of Social Sciences and Law. These faculties together award a range of academic degrees spanning bachelor's and master's degrees as well as junior doctorates and higher doctorates. University of Bristol was established in 1876 and is based in Bristol, United Kingdom.

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to enhance patient identification by reducing heterogeneity and targeting those with similar underlying neurobiological conditions. This approach allows researchers to concentrate on advancing treatments in areas with significant unmet medical needs within the field of neuroscience.

Graphene Trace is a healthcare technology company specializing in the prevention of pressure ulcers. It develops a smart, pressure-sensing fabric that continuously monitors and alerts users and caregivers to potential pressure points, enabling timely repositioning and preventing the formation of ulcers. The fabric is ultra-thin, comfortable, and affordable, making it suitable for use in wheelchairs and hospitals.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

Presymptom Health is a medtech company that specializes in developing clinical decision support algorithms and diagnostic tests aimed at early illness detection. The company focuses on pre-symptomatic diagnostics, allowing for the identification of conditions such as sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health's innovations aim to enhance critical care outcomes and improve patient management. Through its portfolio of blood tests and algorithms, the company seeks to transform the way healthcare providers approach patient care, ultimately contributing to better health outcomes and potentially saving lives.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

Cortirio specializes in the development of portable brain imaging technology aimed at diagnosing and monitoring traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company's innovative portable scanners utilize near-infrared imaging with enhanced spatial resolution to deliver point-of-care medical imaging. This technology enables healthcare providers to access vital information throughout the clinical pathway, facilitating automatic analysis and data transfer. By providing timely and accurate diagnostic capabilities, Cortirio's devices empower clinicians to make quicker decisions, ultimately improving care for patients suffering from brain injuries and strokes.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

Aelius Biotech specializes in creating advanced models of the mucosal surfaces of the human body. The company focuses on developing systems that simulate the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract. Aelius Biotech's model gut system allows healthcare industry participants to simulate essential processes such as digestion, mucus permeation, and epithelial absorption. The company provides a range of testing services, including in vitro and in vivo assessments, simple lab assays, and integrated model gut testing across the aerodigestive tract. Additionally, Aelius Biotech conducts human trials, aiding healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

Lucida Medical is a developer of healthcare technology that utilizes artificial intelligence to enhance the detection and diagnosis of cancer. The company has created software that supports the analysis of MRI scans, focusing on applications for cancer diagnosis, screening, and management. Its flagship product, Pi, is designed specifically for the diagnosis of prostate cancer through multiparametric or diffusion MRI and has received CE marking as a medical device. By integrating imaging and multi-omics biomarkers, Lucida Medical aims to provide clinicians with tools that make cancer detection more accurate, accessible, cost-effective, and rapid. The company is interested in collaborating with investors and hospital partners who share its commitment to early cancer detection.

Mesenbio is a preclinical biopharmaceutical company located at the University of York, specializing in cell-derived therapies. It employs a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which enhances the development of treatments by addressing common challenges in extracellular vesicle therapy. The company is focused on creating innovative treatments for conditions such as arthritis, utilizing engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio aims to improve access to effective therapies for musculoskeletal diseases, thereby contributing to advancements in medical treatment.

The University of Edinburgh, established in 1583, is a prestigious institution located in Edinburgh, United Kingdom. It is renowned globally for its academic excellence, offering a wide range of disciplines, including its renowned Medical School and Law School. As one of Scotland's ancient universities, it is committed to delivering high-quality education, conducting cutting-edge research, and fostering innovation to address global challenges.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

CellRev is a biotechnology company specializing in innovative bioprocessing technologies aimed at improving cell manufacturing for various applications, including cultured meat, cell therapy, and biologics. The company's proprietary technology enables a shift from traditional batch processing to continuous processing of adherent cells, significantly enhancing yield while reducing operating costs and capital expenditures. CellRev's unique cell detachment process, combined with a specially designed bioprocess, addresses critical challenges in manufacturing, such as cell aggregation, clumping, and detachment. This approach allows cell-based vaccine and therapy developers to streamline their production processes, eliminate serum usage, and overcome significant bottlenecks in the industry.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, a group of rare genetic disorders affecting the brain's white matter. The company aims to disrupt existing treatment practices by creating a therapy that addresses the root cause of these diseases, specifically targeting the mutated TUBB4a gene implicated in TUBB4a Leukodystrophy. By leveraging groundbreaking research, SynaptixBio is dedicated to providing potentially curative options for patients suffering from this acute subset of leukodystrophies. The company also maintains an online platform to engage with customers and address inquiries, ensuring transparency and accessibility of information about their advancements.

Spirecut is a MedTech company specializing in innovative surgical instruments designed for the treatment of carpal tunnel syndrome and trigger finger. The company has developed a patented technique for ultrasound-guided surgery that eliminates the need for skin incisions, resulting in no post-operative wounds. This approach allows patients to resume daily activities immediately without the need for dressings or coverings on the operated area. Spirecut's instruments represent a significant advancement over traditional methods, improving upon the simple needles typically used by surgeons and radiologists. The enhanced design facilitates the safe release of thickened tissue and aids in preoperative sonographic tracking, ultimately enabling surgeons to achieve better surgical outcomes and accelerating patient recovery.

Laverock Therapeutics is focused on advancing gene silencing technology to create innovative programmable cell therapies. Their platform enables the engineering of next-generation allogeneic cell therapies that can adapt to both internal and external environmental signals. This capability allows for the development of induced pluripotent stem cell (iPSC)-derived products that offer enhanced efficacy, safety, and accessibility, addressing many of the challenges faced by traditional therapeutic methods. Through its pioneering approach, Laverock Therapeutics aims to facilitate significant advancements in the fields of medicine and biotechnology.

Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.

ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

Jude is a healthcare company focused on addressing bladder health issues and raising awareness about incontinence. The organization offers a range of services that include expert advice from medical professionals through social media, virtual seminars, and private chat options. Additionally, Jude provides health products designed to assist individuals in managing their bladder health effectively. By combining educational resources with accessible support, Jude aims to empower individuals to understand their medical conditions and pursue solutions for a leak-free life.

AstronauTx is a biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative conditions. The company aims to restore the normal functioning of astrocytes, which are crucial cells in the brain that support neuronal activity, metabolism, and the integrity of the blood-brain barrier. In conditions such as dementia, astrocytes can become dysfunctional, leading to neurotoxicity and exacerbating disease progression. By targeting astrocyte homeostasis, AstronauTx seeks to enable healthcare professionals to effectively address the underlying mechanisms of neurotoxicity associated with these diseases, ultimately improving treatment options for patients suffering from dementia and related disorders.

TherageniX specializes in gene therapy for tissue regeneration, focusing on orthopedic applications. The company's patented technology uses a non-viral delivery system to introduce specific genes, such as VEGF and BMP, into autologous bone marrow cells, enhancing their regenerative capacity. This process aids in tissue repair and regeneration, improving functional outcomes and reducing donor site trauma for patients with diseases, injuries, or age-related tissue damage.

Plasticell is a biotechnology company focused on developing innovative therapeutics through advanced cell culture and drug discovery platforms. The company specializes in elucidating the biochemical mechanisms that regulate the proliferation and differentiation of stem cells, which are essential for tissue development and repair. By testing a wide range of cell culture variables, Plasticell aims to establish optimal laboratory protocols for various applications in cell biology, gene transduction, protein production, and drug screening. This approach enables researchers to create novel small molecule drugs that promote regenerative medicine and improve therapeutic outcomes.

NK:IO is a biotechnology company focused on advancing natural killer cell-mediated immunotherapy, particularly in the realm of cancer treatment. The company specializes in developing innovative cell therapies and small molecule therapeutics designed to enhance the effectiveness of cancer targeting for physicians. By leveraging cutting-edge research and technology, NK:IO aims to improve treatment outcomes for patients facing cancer.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Corryn Biotechnologies is a biotechnology company focused on innovating wound care solutions through its Heals device, which offers a contactless method for treating chronic and complex wounds. The company has developed advanced applicators that utilize electrical voltages to extrude fine fibers from various fluids, creating wound dressings that can be made from synthetic or natural materials. These dressings can be enhanced with or without active ingredients and are designed to deposit non-woven meshes for effective Advanced Tissue Repair (ATR). Through this technology, Corryn aims to improve the management and healing of chronic wounds, providing a novel approach to wound dressing.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research, promoting more efficient and ethical cell culture experiments. Backed by prominent UK research councils, Peptimatrix brings together experts in matrix biology, cancer science, toxicology, and biomaterial engineering to create reproducible, reliable, and ethical in vitro disease and development models.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

Autolomous Ltd, founded in 2019 and based in Mayfair, United Kingdom, specializes in developing software solutions for manufacturers of cell and gene therapies. Its flagship platform, autoloMATE®, is a cloud-native system that provides comprehensive support for Advanced Therapies and Vector manufacturing processes. The software facilitates the scheduling of patient cell collections, the transport of these cells to production sites, and the tracking of manufacturing processes to ensure compliance with regulatory standards. It also supports the legal release and timely delivery of patient-specific medicines. The highly configurable platform allows clients to customize workflows and integrates seamlessly with existing systems. Autolomous emphasizes data security by utilizing blockchain technology to maintain the integrity of manufacturing data. The company adheres to strict regulatory guidelines and has achieved several ISO certifications, reflecting its commitment to quality management and environmental standards.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

GG Care helps care residents stay independent and help carers monitor their well-being, comfort, and mood. They serve people with dementia maintain daily routines and stay socially connections shown to reduce cognitive decline and increase happiness and creates an environment to help reduce agitation - significantly reducing the cost of care.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

SyncVR Medical is dedicated to enhancing healthcare through virtual and augmented reality (VR/AR) solutions. As the largest XR platform for healthcare in Europe and the UK, the company serves over 125 healthcare institutions across several countries, including the Netherlands, Germany, Denmark, Sweden, Belgium, the UK, and France. SyncVR Medical's platform offers a range of applications designed to support patient care, alleviate pain and anxiety, and improve treatment outcomes based on scientific research. Additionally, more than 25 third-party developers contribute to the platform, providing access to a broader customer base in the healthcare sector. SyncVR Medical aims to establish itself as the leading XR platform in the top five European healthcare markets by 2025.

ScubaTx focuses on developing an organ preservation system that utilizes the Persufflation method, which is known for its effectiveness in preserving organs during transportation. By enhancing the condition of grafts during preservation, ScubaTx enables healthcare providers to expand the availability of viable organs for transplantation. The company aims to improve organ preservation practices through innovative software design, ultimately delivering significant cost savings to healthcare providers. This advancement not only enhances the quality of organ transplants but also contributes to increasing the overall supply of life-saving organs available to patients in need.

Lindus Health is a clinical research organization focused on delivering comprehensive clinical trial services for health and biotech companies. The company offers a range of solutions, including ethics and IRB submission, trial monitoring, data management, biostatistics, regulatory support, and payer affairs. By utilizing a proprietary software platform, Lindus Health automates various aspects of the clinical trial workflow, which streamlines operations and minimizes manual inefficiencies. This platform also facilitates access to electronic health records, enhancing patient recruitment and clinical data capture. Furthermore, Lindus Health leverages real-world patient data to improve trial design and execution, ultimately aiming to accelerate the clinical trial process while reducing risks and costs associated with trial failures.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

Nanovery Limited, founded in 2018 and based in London, United Kingdom, specializes in developing nanorobots aimed at detecting cancer mutations. The company's innovative platform utilizes artificial intelligence to facilitate the rapid and ultra-sensitive identification of challenging biomarkers in blood samples. These nanorobots can capture circulating tumor DNA and emit a fluorescent signal, enabling healthcare professionals to conduct point-of-care tests. By facilitating early cancer detection, Nanovery aims to enhance patient outcomes and increase survival rates. The organization is supported by a team of experts in nanotechnology, medicinal chemistry, and artificial intelligence, along with backing from leading academics, clinicians, and industry leaders.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

Doctoria is a virtual healthcare platform to enable doctors and patients to connect better.

Lightox specializes in developing advanced molecular tools for imaging, therapeutics, and assay development, focusing on innovative cancer treatments. The company has created a range of light-activated drug compounds designed to selectively target and eliminate tumor cells while minimizing harm to surrounding healthy tissue. Their unique fluorescent probes are smaller than any other products currently available, allowing for versatile applications in research and clinical settings. These probes can function as freely-moving agents that easily integrate into cells, or they can be customized with flexible linkers to meet specific research requirements. Lightox aims to enhance patient outcomes by providing more efficient cancer treatment options.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Its technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

NIQS Tech is a spin-out from the University of Leeds that specializes in quantum technology, specifically focusing on non-invasive glucose monitoring for diabetes management. The company has developed a patented wearable monitor that utilizes nano-engineered glass to continuously and accurately measure glucose levels without the need for needles or blood. This user-friendly technology aims to provide actionable insights that empower individuals living with diabetes to manage their condition effectively and improve their overall quality of life. By eliminating the need for traditional glucose management methods, NIQS Tech seeks to reduce the risk of diabetes-related complications and enhance the well-being of its users.

Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

The Medicines Discovery Catapult is the centre of national expertise for the discovery of medicines.

eMoodie is a technology company that has developed an app designed for ecological momentary assessment research, focusing on mental health, emotions, and socialization patterns in children and adolescents. The app, designed as a research tool, examines symptoms, feelings, and health aspects, including sleep, in older kids, teenagers, and adults. It also enables parents to monitor and mitigate the digital mental impact on their children.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Drill Surgeries is a technology company specializing in AI-powered surgical navigation systems for trauma and orthopedic procedures. Their proprietary AI algorithms and mixed reality technologies aim to significantly reduce operating room time and enhance surgical precision, thereby minimizing failure rates and unnecessary radiation exposure. By doing so, they help hospitals save substantial costs per operation.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. Its offerings include induced pluripotent stem cells, human and multispecies primary cells, and a comprehensive cell culture and analysis package. The company utilizes advanced devices such as micro physiological systems and microfluidic designs to enhance drug discovery. One of its notable projects, "Liver on chip," focuses on liver toxicity testing and incorporates techniques like cellular reprogramming and organ-on-chip technology. Stemnovate also offers services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Neumind is a developer of technological solutions aimed at assisting individuals with neurological conditions and injuries. Founded in 2019 and based in Great Shelford, Cambridge, the company offers an app named Alfred, which provides both practical and therapeutic support to users and their caregivers. Alfred leverages smartphone technology to enhance cognitive functions, stimulate neural pathways, and promote behaviors and strategies grounded in neurorehabilitation and cognitive behavioral science. This application is designed to help individuals manage various neurological issues, such as brain injuries and dementia, enabling them to lead more independent, functional, and fulfilling lives.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

NRG Therapeutics is a drug discovery company established in 2018 that specializes in developing therapeutic approaches aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and motor neuron disease. The company focuses on creating novel medicines that preserve mitochondrial function and halt disease progression. With a team experienced in neuroscience drug discovery, NRG Therapeutics is initially concentrating on the discovery and development of brain-penetrant inhibitors of the mitochondrial permeability transition pore specifically for Parkinson’s disease. This strategic focus is intended to empower physicians with effective treatment options for patients suffering from chronic neurodegenerative disorders.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.

We already know that upto 50% of patients struggle to take their medicines – patients are not well-supported and too often it remains a hidden problem until it's too late. CONNECT Care want to change that: empowering patients and, at the same time, using data-driven insights to enable clinicians and carers to provide better support in real-time.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.